the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

Exclusion Criteria

• •1. Patients with fully HLA-matched donors;
• •2. Received allogeneic transplantation, which needs to be weighed and evaluated by an expert committee; received other gene therapies;
• •3. Have previously undergone splenectomy;
• •4. Uncorrected bleeding disorder;
• •5. Uncontrolled epilepsy and mental illness;
• •6. Received hydroxyurea, ruxolitinib, decitabine, or cytarabine within 3 months prior to enrollment;
• •7. Psychoactive substance abuse, drug or alcohol abuse within 6 months prior to enrollment;
• •8. Patients with pulmonary hypertension who have not been given effective intervention;
• •9. Persistent toxicity (≥ CTCAE grade 2) induced by previous treatment;
• •10. Positive for anti-RBC antibodies in antibody screening;
• •11. Positive for hepatitis B surface antigen (HBsAg) and HBV DNA copy number \> upper limit of normal (ULN) (HBV DNA test not required for patients negative for HBsAg), positive for hepatitis C virus (HCV) antibody, positive human immunodeficiency virus (HIV), or positive for Treponema pallidum antibody (TP-Ab) (subjects who are positive for the antibody due to vaccination can be enrolled). In certain clinical environments/regions, subjects who are positive for other tests can also be excluded from the trial, such as, human lymphocytic virus-1 (HTLV-1) or -2 (HTLV-2), tuberculosis, and toxoplasmosis.
• •12. Has or has had malignant tumors or myeloproliferative disease or immunodeficiency disease;
• •13. Immediate family member with or suspected of having a familial cancer (including but not limited to hereditary breast and ovarian cancers, nonpolyposis colorectal cancer, and adenomatous polyposis);
• •14. Severe bacterial, viral, fungal or parasitic infection;
• •15. Other illnesses which render the subject unsuitable for participation (e.g., severe liver, kidney or heart disease); Definition of severe liver and kidney disease: a. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin \> 3 × ULN; b. Liver magnetic resonance imaging (MRI) indicates significant cirrhosis; c. Liver biopsy indicates cirrhosis, severe fibrosis or active hepatitis (liver biopsy is only performed when liver MRI indicates active hepatitis and significant fibrosis without evidence for cirrhosis); d. Creatinine clearance \< 30% of normal;
• •16. WBC \< 3 × 109/L and/or PLT \< 100 × 109/L;
• •17. Has diabetes, abnormal thyroid functions or other endocrine disorder;
• •18. Participated in other interventional clinical studies within 4 weeks before the trial;
• •19. Poor adherence or other conditions that renders the subject unsuitable for participation as judged by the investigator.